$247 Million is the total value of Tri Locum Partners LP's 73 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTGX | PROTAGONIST THERAPEUTICS INCcall | $2,177,000 | +29.4% | 199,500 | 0.0% | 0.88% | +90.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FEMASYS INC | 10 | Q3 2023 | 0.5% |
| REGENERON PHARMACEUTICALS | 9 | Q3 2023 | 13.8% |
| LILLY ELI & CO | 9 | Q2 2023 | 9.5% |
| X4 PHARMACEUTICALS INC | 8 | Q3 2023 | 3.0% |
| XENON PHARMACEUTICALS INC | 8 | Q3 2023 | 2.4% |
| ARGENX SE | 7 | Q3 2023 | 12.8% |
| STEVANATO GROUP S P A | 7 | Q2 2023 | 5.8% |
| PROTAGONIST THERAPEUTICS INC | 7 | Q2 2023 | 7.1% |
| AVADEL PHARMACEUTICALS PLC | 7 | Q3 2023 | 6.4% |
| BELLUS HEALTH INC NEW | 7 | Q3 2022 | 4.3% |
View Tri Locum Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-27 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Tri Locum Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.